1990 : 1990 ZPHC GHK-Cu ( -1) : ,
Numerous investigational therapies targeting inflammation, oxidative stress, liver regeneration, bile acid signalling, epigenetic regulation, and the gut-liver axis have been evaluated, with largely disappointing results
Diab Care 45 , 909918 (2022)
It was developed to provide a chemically well-characterised molecule suitable for controlled investigation of short peptide signalling in cellular and molecular research systems
At the maximum 2.4mg dose, just over 2 weeks
Click for pricing breakdown How do I prepare for B12 injections